91 related articles for article (PubMed ID: 9570686)
1. Soluble molecules as biological markers in Hodgkin's disease.
Nadali G; Vinante F; Chilosi M; Pizzolo G
Leuk Lymphoma; 1997 Dec; 26 Suppl 1():99-105. PubMed ID: 9570686
[TBL] [Abstract][Full Text] [Related]
2. Soluble ICAM-1 in Hodgkin's disease: a promising independent predictive marker for survival.
Christiansen I; Enblad G; Kälkner KM; Gidlöf C; Glimelius B; Tötterman TH
Leuk Lymphoma; 1995 Oct; 19(3-4):243-51. PubMed ID: 8535215
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma.
Gause A; Jung W; Schmits R; Tschiersch A; Scholz R; Pohl C; Hasenclever D; Diehl V; Pfreundschuh M
Ann Oncol; 1992 Sep; 3 Suppl 4():49-52. PubMed ID: 1333270
[TBL] [Abstract][Full Text] [Related]
4. Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies.
Srivastava MD; Srivastava A; Srivastava BI
Leuk Lymphoma; 1994 Jan; 12(3-4):241-51. PubMed ID: 7909467
[TBL] [Abstract][Full Text] [Related]
5. Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease.
Axdorph U; Sjöberg J; Grimfors G; Landgren O; Porwit-MacDonald A; Björkholm M
Ann Oncol; 2000 Nov; 11(11):1405-11. PubMed ID: 11142480
[TBL] [Abstract][Full Text] [Related]
6. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome.
Nadali G; Tavecchia L; Zanolin E; Bonfante V; Viviani S; Camerini E; Musto P; Di Renzo N; Carotenuto M; Chilosi M; Krampera M; Pizzolo G
Blood; 1998 Apr; 91(8):3011-6. PubMed ID: 9531614
[TBL] [Abstract][Full Text] [Related]
7. The clinical significance of cytokines and soluble forms of membrane-derived activation antigens in the serum of patients with Hodgkin's disease.
Gause A; Jung W; Keymis S; Schobert I; Scholz R; Schmits R; Diehl V; Pohl C; Hasenclever D; Pfreundschuh M
Leuk Lymphoma; 1992 Aug; 7(5-6):439-47. PubMed ID: 1283546
[TBL] [Abstract][Full Text] [Related]
8. [Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas].
Iaguzhinskaia OE; Lazarev IE; Nikitin EA; Samoĭlova RS; Loginova IV; Gemdzhan EG; Novikov VA; Mamiliaeva ZKh; Pivnik AV
Ter Arkh; 2001; 73(4):45-51. PubMed ID: 11494447
[TBL] [Abstract][Full Text] [Related]
9. Soluble vascular cell adhesion molecule-1 (sVCAM-1) is an independent prognostic marker in Hodgkin's disease.
Christiansen I; Sundström C; Enblad G; Tötterman TH
Br J Haematol; 1998 Aug; 102(3):701-9. PubMed ID: 9722296
[TBL] [Abstract][Full Text] [Related]
10. Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis.
Vener C; Guffanti A; Pomati M; Colombi M; Alietti A; La Targia ML; Bamonti-Catena F; Baldini L
Leuk Lymphoma; 2000 Apr; 37(3-4):333-9. PubMed ID: 10752984
[TBL] [Abstract][Full Text] [Related]
11. Biopathologic features of Hodgkin's disease.
Chilosi M; Pizzolo G
Leuk Lymphoma; 1995 Feb; 16(5-6):385-95. PubMed ID: 7787748
[TBL] [Abstract][Full Text] [Related]
12. Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2alphaR levels in non-Hodgkin's lymphoma.
Pérez-Encinas M; Quintas A; Bendaña A; Rabuñal MJ; Bello JL
Leuk Lymphoma; 1999 May; 33(5-6):551-8. PubMed ID: 10342582
[TBL] [Abstract][Full Text] [Related]
13. Correlation between clinical features and circulating levels of soluble intercellular adhesion molecule-1 in Hodgkin's disease.
Nadali G; Vinante F; Rigo A; Tecchio C; Morosato L; Zanolin E; Perona G; Chilosi M; Pizzolo G
Int J Clin Lab Res; 1995; 25(2):84-7. PubMed ID: 7663010
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of soluble adhesion molecules in Hodgkin's disease.
Syrigos KN; Salgami E; Karayiannakis AJ; Katirtzoglou N; Sekara E; Roussou P
Anticancer Res; 2004; 24(2C):1243-7. PubMed ID: 15154654
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
Bien E; Balcerska A
Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage.
Pizzolo G; Vinante F; Chilosi M; Dallenbach F; Josimovic-Alasevic O; Diamantstein T; Stein H
Br J Haematol; 1990 Jun; 75(2):282-4. PubMed ID: 2164839
[TBL] [Abstract][Full Text] [Related]
17. Serum soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in Crohn's disease, celiac disease, and systemic lupus erythematosus.
Srivastava MD; Rossi TM; Lebenthal E
Res Commun Mol Pathol Pharmacol; 1995 Jan; 87(1):21-6. PubMed ID: 7735726
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease.
Gause A; Pohl C; Tschiersch A; Da Costa L; Jung W; Diehl V; Hasenclever D; Pfreundschuh M
Blood; 1991 May; 77(9):1983-8. PubMed ID: 1850308
[TBL] [Abstract][Full Text] [Related]
19. Soluble CD30: a possible serum tumor marker for primary effusion lymphoma.
Michai M; Goto H; Hattori S; Vaeteewoottacharn K; Wongkham C; Wongkham S; Okada S
Asian Pac J Cancer Prev; 2012; 13(10):4939-41. PubMed ID: 23244086
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis.
Nadali G; Vinante F; Ambrosetti A; Todeschini G; Veneri D; Zanotti R; Meneghini V; Ricetti MM; Benedetti F; Vassanelli A
J Clin Oncol; 1994 Apr; 12(4):793-7. PubMed ID: 8151321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
